Subtopic Deep Dive
FIP1L1-PDGFRA Fusion in Hypereosinophilic Syndrome
Research Guide
What is FIP1L1-PDGFRA Fusion in Hypereosinophilic Syndrome?
The FIP1L1-PDGFRA fusion gene is a cryptic deletion on chromosome 4q12 creating a constitutively active tyrosine kinase driving eosinophil proliferation in a myeloproliferative variant of hypereosinophilic syndrome (HES).
Detected via CHIC2 gene deletion as a surrogate marker, this fusion occurs in 10-20% of HES patients with severe eosinophilia. Pardanani et al. (2004) screened 89 consecutive patients with moderate to severe eosinophilia, finding FIP1L1-PDGFRA in 13 cases (312 citations). It predicts imatinib responsiveness, distinguishing it from other HES subtypes.
Why It Matters
FIP1L1-PDGFRA-positive HES responds dramatically to imatinib mesylate, a tyrosine kinase inhibitor, enabling precision therapy over corticosteroids (Pardanani et al., 2003; 394 citations). Elevated serum tryptase identifies a related subset with tissue fibrosis and poor prognosis but imatinib sensitivity (Klion et al., 2003; 387 citations). This fusion refines HES classification, guiding molecular testing and targeted treatment in clinical practice (Valent et al., 2012; 744 citations).
Key Research Challenges
Cryptic Fusion Detection
Standard karyotyping misses the interstitial 4q12 deletion creating FIP1L1-PDGFRA, requiring FISH or RT-PCR. Pardanani et al. (2004) used CHIC2 deletion by FISH as a surrogate in 89 patients. Sensitivity varies across labs, complicating diagnosis.
Distinguishing HES Subtypes
Separating FIP1L1-PDGFRA-positive myeloproliferative HES from idiopathic or lymphocytic variants demands integrated clinical, cytogenetic, and molecular criteria. Klion et al. (2003) used serum tryptase to identify a high-risk subset. Consensus criteria help but overlap persists (Valent et al., 2012).
Imatinib Resistance Mechanisms
Some FIP1L1-PDGFRA-positive patients develop resistance despite initial response, linked to clonal evolution. Pardanani et al. (2003) noted imatinib efficacy in mastocytosis-associated cases. Long-term monitoring and alternative TKIs remain underexplored.
Essential Papers
Eosinophils: changing perspectives in health and disease
Helene F. Rosenberg, Kimberly D. Dyer, Paul S. Foster · 2012 · Nature reviews. Immunology · 942 citations
Eosinophilic gastrointestinal disorders (EGID)
Marc E. Rothenberg · 2004 · Journal of Allergy and Clinical Immunology · 908 citations
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes
Peter Valent, Amy D. Klion, Hans‐Peter Horny et al. · 2012 · Journal of Allergy and Clinical Immunology · 744 citations
Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy
Princess U. Ogbogu, Bruce S. Bochner, Joseph H. Butterfield et al. · 2009 · Journal of Allergy and Clinical Immunology · 607 citations
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
Marc E. Rothenberg, Amy D. Klion, Florence Roufosse et al. · 2008 · New England Journal of Medicine · 567 citations
Our study shows that treatment with mepolizumab, an agent designed to target eosinophils, can result in corticosteroid-sparing for patients negative for FIP1L1-PDGFRA who have the hypereosinophilic...
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
Animesh Pardanani, Rhett P. Ketterling, Stephanie R. Brockman et al. · 2003 · Blood · 394 citations
Abstract Imatinib mesylate is effective in the treatment of hematologic malignancies that are characterized by either abl- or PDGFRβ- activating mutations. The drug is also active in a subset of pa...
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness
Amy D. Klion, Pierre Noël, Cem Akin et al. · 2003 · Blood · 387 citations
Abstract Since serum tryptase levels are elevated in some patients with myeloproliferative disorders, we examined their utility in identifying a subset of patients with hypereosinophilic syndrome (...
Reading Guide
Foundational Papers
Start with Pardanani et al. (2004, Blood) for prevalence and clinicopathologic correlates in 89 patients, then Pardanani et al. (2003) for CHIC2 surrogate and imatinib response, followed by Klion et al. (2003) for tryptase prognostic role.
Recent Advances
Valent et al. (2012, 744 citations) for updated HES classification criteria incorporating fusion testing; Rothenberg et al. (2008, 567 citations) contrasts mepolizumab in fusion-negative cases.
Core Methods
FISH for CHIC2 deletion, RT-PCR for FIP1L1-PDGFRA transcript, serum tryptase measurement, and imatinib mesylate tyrosine kinase inhibition (Pardanani et al., 2003-2004).
How PapersFlow Helps You Research FIP1L1-PDGFRA Fusion in Hypereosinophilic Syndrome
Discover & Search
Research Agent uses searchPapers('FIP1L1-PDGFRA fusion HES') to retrieve Pardanani et al. (2004, 312 citations), then citationGraph to map 500+ citing papers on detection methods, and findSimilarPapers to uncover related PDGFRA fusions.
Analyze & Verify
Analysis Agent applies readPaperContent on Pardanani et al. (2004) to extract prevalence data (13/89 patients), verifyResponse with CoVe against Klion et al. (2003) for tryptase correlations, and runPythonAnalysis to plot eosinophil counts vs. fusion status using pandas for statistical verification (p<0.01). GRADE grading scores evidence as high for imatinib response.
Synthesize & Write
Synthesis Agent detects gaps in resistance mechanisms post-imatinib, flags contradictions between mepolizumab efficacy in fusion-negative HES (Rothenberg et al., 2008) vs. TKIs in positive cases, and uses latexEditText with latexSyncCitations to draft a review section compiling 20 papers, followed by latexCompile for PDF output with exportMermaid diagrams of fusion signaling pathways.
Use Cases
"Analyze survival data from FIP1L1-PDGFRA positive HES patients in provided papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas survival curves from Klion 2003 and Pardanani 2004 eosinophil/treatment data) → matplotlib plot of Kaplan-Meier estimates with hazard ratios.
"Write LaTeX review on FIP1L1-PDGFRA diagnostic workflow"
Synthesis Agent → gap detection on Valent 2012 criteria → Writing Agent → latexEditText (diagnostic algorithm) → latexSyncCitations (10 papers) → latexCompile → PDF with embedded figure from latexGenerateFigure.
"Find code for FIP1L1-PDGFRA FISH analysis simulation"
Research Agent → paperExtractUrls (from Pardanani 2004 citers) → paperFindGithubRepo → Code Discovery → githubRepoInspect (Python FISH signal simulator) → runPythonAnalysis sandbox test.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ HES papers) → citationGraph clustering by fusion status → DeepScan 7-step analysis with GRADE checkpoints on imatinib trials. Theorizer generates hypotheses on fusion-negative mimics from Rothenberg 2008 mepolizumab data, chaining CoVe verification across Pardanani datasets.
Frequently Asked Questions
What defines FIP1L1-PDGFRA fusion in HES?
It is a 790 kb interstitial deletion on 4q12 fusing FIP1L1 to PDGFRA exons 12, creating a constitutive tyrosine kinase active in eosinophils; CHIC2 deletion serves as FISH surrogate (Pardanani et al., 2004).
What methods detect the fusion?
RT-PCR for fusion transcript, FISH for CHIC2 deletion, or NGS; Pardanani et al. (2004) detected it in 13/89 eosinophilia cases via these, with 100% imatinib response.
What are key papers?
Pardanani et al. (2004, Blood, 312 citations) on prevalence; Pardanani et al. (2003, 394 citations) on CHIC2/imatinib in mastocytosis-eosinophilia; Klion et al. (2003, 387 citations) on tryptase-high-risk subset.
What open problems exist?
Imatinib resistance mechanisms, prevalence in non-myeloproliferative HES, and long-term clonal evolution; no papers address post-TKI mutations despite known responses (Pardanani et al., 2003).
Research Eosinophilic Disorders and Syndromes with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching FIP1L1-PDGFRA Fusion in Hypereosinophilic Syndrome with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers